Elon Musk’s Neuralink Projects $1 Billion Revenue by 2031, Targets 20,000 Brain Implants Annually
Elon Musk’s brain-interface company, Neuralink Corp., is aiming to generate over $1 billion in annual revenue by 2031, with plans to implant brain chips in 20,000 people each year, according to internal documents obtained by Bloomberg.
The ambitious forecast reflects Musk’s vision of a future where brain-computer interfaces (BCIs) become mainstream medical tools. Despite currently being in the early stages of human testing—with fewer than 10 individuals known to have received implants—Neuralink anticipates receiving U.S. regulatory approval for its first commercial device, Telepathy, by 2029.
Telepathy will enable users to control digital devices using only their thoughts, marking a major leap in assistive technology for people with paralysis. The company also plans to introduce two additional products: Blindsight, aimed at restoring vision for blind individuals by 2030, and Deep, designed to treat neurological conditions such as tremors and Parkinson’s disease.
Neuralink’s investor presentation outlines plans to open five major surgical clinics by 2030, ramping up to 10,000 implant procedures per year by that time. At an estimated reimbursement rate of $50,000 per surgery, the company projects $500 million in annual revenue from Blindsight alone.
To date, Neuralink has raised approximately $1.3 billion in funding and is valued at $9 billion, according to data from PitchBook. It joins a growing number of startups exploring the rapidly evolving neurotechnology space, a field that has gained traction among both technologists and medical researchers.
However, Neuralink’s path forward is not without obstacles. The U.S. Food and Drug Administration (FDA) has yet to approve any BCI device for permanent use in humans, and long-term safety and efficacy remain central concerns. Other companies in the field face similar regulatory and scientific challenges.
Still, Neuralink’s bold projections and expanding roadmap suggest that Musk’s latest venture is betting heavily on a future where mind-controlled technology becomes a cornerstone of modern medicine.
